Navigation Links
Blood-Thinner No Help for Dialysis Treatment
Date:5/13/2008

Plavix didn't improve results for patients who underwent circulatory procedure

TUESDAY, May 13 (HealthDay News) -- A major trial has dashed the hope that the clot-preventing drug Plavix could help in the delicate balancing act needed to establish a blood vessel suitable for dialysis for kidney patients.

Giving Plavix (clopidogrel) did reduce the risk that a blood clot would block the vessel created by combining a vein and an artery, a standard procedure for kidney dialysis. But adding the clot-preventing drug did not increase the number of fistulas, as they are called, that could be used for artificial kidney treatment over the long run, the study authors reported.

The study was done because "early thrombosis [blood clotting] is one of the major causes of fistula failure," said Dr. Laura M. Dember, an associate professor of medicine at Boston University, and lead author of the report.

"What we found was that despite the reduction in thrombosis that was clear enough, there was an equal proportion of fistula failure," Dember said. "What is ultimately important is the usability of the fistula for dialysis."

The researchers published their findings in the May 14 issue of the Journal of the American Medical Association.

About 470,000 Americans have kidney failure and are kept alive by dialysis, in which their blood is run through a machine that filters out impurities. The preferred technique for linking to the artificial kidney is to create a fistula, which has lower rates of thrombosis -- blockage -- and infection than alternatives such as synthetic artery-vein grafts. But many fistulas never mature enough to allow dialysis.

The multi-center trial included 877 people with total or partial kidney failure who underwent surgery to create a fistula. Half were given Plavix for six weeks after the surgery, while the other half were not.

Plavix did reduce the risk of blockage by 37 percent over the six-week period. Among the 866 people who were tested, 12.2 percent of those given Plavix had a blockage, compared to 19.5 percent of those not given the anti-clotting drug.

But Plavix therapy did not reduce the incidence of cases in which the fistula could not be used for dialysis, which was 61.8 percent in those getting the drug and 59.5 percent in those getting a placebo.

The rate of fistula failure was about 50 percent higher than anticipated, Dember said, and that might have an effect on future practice.

"There has been an increased emphasis on trying to create fistulas in as many patients as possible," she said. "So, the criteria have changed. We need to develop better methods for selecting suitable candidates for fistula creation."

The trial also indicated the direction that that research should take, Dember said.

"Our future efforts should be directed at understanding the basic mechanisms of fistula maturation," she said. "If we better understand those mechanisms, we should be able to identify maturity-enhancing interventions."

More information

The basics of kidney dialysis are explained by the U.S. National Library of Medicine.



SOURCES: Laura M. Dember, M.D., associate professor of medicine, Boston University School of Medicine; May 14, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Mix-Up Behind FDAs Failure to Inspect China Blood-Thinner Plant
2. Blood-Thinner Contaminant Traced to Chinese Plant
3. Clinical trials present better alternatives for dialysis patients
4. Nighttime Home Dialysis a Boon for Kidney Patients
5. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
6. WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA
7. New peritoneal dialysis diagnostic discovered
8. Early intervention dramatically improves outcomes for new dialysis patients
9. Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date
10. Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
11. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: